Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
REDWOOD CITY, Calif., Dec. 14, 2020 Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum’s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co.
“Dawn is a highly-esteemed industry veteran who brings extensive global commercial leadership experience to the board,” said Laurent Fischer, M.D., chief executive officer of Adverum Biotechnologies. “We have begun to build pre-commercial capabilities as we aim to advance ADVM-022 toward our first Phase 2b pivota
Is IRDM A Good Stock To Buy Now? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Share:
REDWOOD CITY, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum s Board of Directors. Ms. Svoronos has three decades of global biopharmaceutical industry experience, spanning the United States, Canada, Europe, and Asia, gained during her 25-year career at Merck & Co. Dawn is a highly-esteemed industry veteran who brings extensive global commercial leadership experience to the board, said Laurent Fischer, M.D., chief executive officer of Adverum Biotechnologies. We have begun to build pre-commercial capabilities as we aim to advance ADVM-022 toward our first Phase 2b pivotal trial in mid-2021. Since ADVM-022 is in development for two large ocular disease indications, wet AMD and DME, it is critical to be prepared for global commercialization. Dawn will prov
GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development Global Blood Therapeutics, Inc. South San Francisco, California, UNITED STATES
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development.
“As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management team and to lead this critical effort,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Kim
Biotechs Rally to Record on Vaccine Distribution, Deal Optimism 1490wosh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 1490wosh.com Daily Mail and Mail on Sunday newspapers.